Clinical Trial Update: Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial by Allon Therapeutics evaluating safety, tolerability, and efficacy in mild cognitive impairment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Snippet

Sponsor: Allon Therapeutics | Conditions: Mild Cognitive Impairment, So Stated | Phase 2 | Status: COMPLETED